• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Tocilizumab reduced COVID-19 disease related adverse health outcomes

byConstance Wu
March 10, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2. Treatment with tocilizumab did not improve survival among patients.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Cases pertaining to the coronavirus disease 2019 (Covid-19) have led to severe clinical manifestations requiring mechanical ventilation. However, fatal outcomes have still resulted given the current support and treatment. This trial investigated the safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in patients hospitalized with Covid-19 pneumonia. These hospitalized patients were randomly assigned into one of two groups after the informed consent was obtained. Patients were followed for two months and outcomes such as the need for mechanical ventilation or death were assessed on day 28. The trial results displayed both increased efficacy and safety in the tocilizumab group. However, both groups revealed similar death outcomes. The study was strengthened by its focus on the inclusion of ethnic and racial minority patients. Conversely, the study was limited by the short follow-up period. Nonetheless, the study results are important as they showed tocilizumab reduces adverse health outcomes related to Covid-19.

Click to read the study in NEJM

Relevant Reading: Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US

In-Depth [randomized controlled trial]: This phase 3, double-blind trial enrolled 389 across multiple countries including Brazil, Kenya, Mexico, Peru, South Africa, and the United States. This study enrolled patients over the age of 18 with confirmed COVID-19 pneumonia who were hospitalized. Patients were excluded if they required additional breathing assistance such as continuous positive airway pressure, mechanical ventilation, or bilevel positive airway pressure. Patients were randomized in a 2:1 ratio to the standard of care including one or two doses of either tocilizumab or a placebo, respectively. On day 28, the primary endpoint of mechanical ventilation or death was evaluated for all participants. The results were further investigated using analysis and stratification, where the median follow-up time was 60 days. By day 28, an overall of 12% (95% confidence interval [CI], 8.5-16.9) of the patients in tocilizumab group had either received some form of mechanical ventilation or had died, whereas a total of 19.3% (95% CI, 13.3-27.4) were reported with similar outcomes in the placebo group. The hazard ratio for mechanical ventilation or death between both groups was 0.56 (95% CI, 0.33-0.97); P = 0.04). Furthermore, 15.2% of the patients reported serious adverse events in the study drug group compared to 19.7% were reported in the placebo. Consequently, more deaths were reported in the placebo group (29 patients) compared to the tocilizumab group (15 patients). Overall, the tocilizumab showed favorable results in the relation to safety and efficacy for Covid-19 pneumonia.

RELATED REPORTS

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: CoronavirusSARS-CoV-2Tocilizumabventilationviralvirus
Previous Post

Radiolabeled Lutetium-177 offers higher PSA response versus cabazitaxel in metastatic castration-resistant prostate cancer

Next Post

Nivolumab and cabozantinib superior to sunitinib for advanced renal-cell carcinoma

RelatedReports

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients
StudyGraphics

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

June 30, 2022
Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

June 22, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

May 13, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

May 13, 2022
Next Post
Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]

Nivolumab and cabozantinib superior to sunitinib for advanced renal-cell carcinoma

Women electing abortion more likely to be victims of domestic violence

Different gestational diabetes screening methods cause no difference for complications

Fluorophores enhance visualization for image-guided surgery [PreClinical]

Whole-genome sequencing more accurate than cytogenetic analysis in myeloid cancers

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.